TUESDAY, Feb. 3, 2026 (HealthDay News) — Middle-aged women with elevated insulin levels might be in for a tougher menopause experience, a new study says.Women w

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide. The findings, published in The Lancet Obstetrics, Gyn...

Although progress against cardiovascular disease—the leading cause of death globally—has extended life expectancy, the rise of diabetes has begun to erode these gains.1 As with any public health issue...

New disease-modifying therapies, such as teplizumab, offer opportunities to delay the clinical onset of type 1 diabetes but require islet autoantibody screening to identify individuals at increased ri...

A longstanding goal in the treatment of osteoporosis has been rejuvenating the ageing skeleton to essentially reverse or cure osteoporosis. Although antiresorptive drugs such as bisphosphonates or den...

In postmenopausal women at high risk of fracture, 3 months of romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab in increasing total hip BMD. Given the expense,...

The European Diabetes Forum (EUDF) welcomes the Safe Hearts Plan1 for cardiovascular health in the EU, released on Dec 16, 2025. We strongly support the Safe Hearts Plan's integrated approach to diabe...

Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger R...

Breast cancer risk is a central concern in shared decision-making when considering menopausal hormone treatment (MHT). Women spend approximately 40% of their lives in menopause, and climacteric sympto...

The global prevalence of type 2 diabetes has risen dramatically over recent decades, fuelled primarily by the growing burden of obesity and characterised by an earlier onset and a multifaceted spectru...

Type 1 diabetes is a chronic autoimmune inflammatory disease resulting in loss of insulin-secreting β cells and the subsequent need for lifelong insulin therapy.1 Presymptomatic type 1 diabetes is marked by the presence of two or more islet autoantibodies. Detection at this early stage offers substantial benefits, including improved long-term glucose control, preparation time for insulin therapy, and a reduced risk of diabetic emergencies, such as diabetic ketoacidosis.2 Furthermore, the advent of disease-modifying therapies to delay the need for insulin makes it crucial to identify type 1 diabetes at the presymptomatic stage.

Familial hypercholesterolaemia is one of the most common inherited metabolic disorders, with heterozygous familial hypercholesterolaemia (HeFH) affecting more than 30 million individuals worldwide, a ...

Addison's disease is the manifestation of adrenal glucocorticoid and mineralocorticoid deficiency from T-cell mediated destruction of the adrenal cortex, and is the commonest cause of primary adrenal ...

ALT: a man with a beard is smiling and looking through a hole in a door .

Endocrine scientists around the world can now access dkNET, a research portal established by the National Institute of Diabetes and Digestive and Kidney Diseases, which provides endocrine researchers ...